Long-Term Outcome of Neuro-Behçet's Disease
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Titre :
Long-Term Outcome of Neuro-Behçet's Disease
Auteur(s) :
Noel, Nicolas [Auteur]
Bernard, Remy [Auteur]
Laboratoire de Physique des Lasers, Atomes et Molécules - UMR 8523 [PhLAM]
Wechsler, Bertrand [Auteur]
Resche-Rigon, Matthieu [Auteur]
Biostatistique et épidemiologie clinique
Depaz, Raphaël [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Boutin, Du Le Thi Huong [Auteur]
Piette, Jean Charles [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Drier, Aurélie [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Dormont, Didier [Auteur]
Algorithms, models and methods for images and signals of the human brain = Algorithmes, modèles et méthodes pour les images et les signaux du cerveau humain [ICM Paris] [ARAMIS]
Cacoub, Patrice [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Biologie et thérapeutique des pathologies immunitaires [BTPI]
Saadoun, David [Auteur]
Immunologie - Immunopathologie - Immunothérapeutique [I3]
Bernard, Remy [Auteur]
Laboratoire de Physique des Lasers, Atomes et Molécules - UMR 8523 [PhLAM]
Wechsler, Bertrand [Auteur]
Resche-Rigon, Matthieu [Auteur]
Biostatistique et épidemiologie clinique
Depaz, Raphaël [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Boutin, Du Le Thi Huong [Auteur]
Piette, Jean Charles [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Drier, Aurélie [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Dormont, Didier [Auteur]
Algorithms, models and methods for images and signals of the human brain = Algorithmes, modèles et méthodes pour les images et les signaux du cerveau humain [ICM Paris] [ARAMIS]
Cacoub, Patrice [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Biologie et thérapeutique des pathologies immunitaires [BTPI]
Saadoun, David [Auteur]
Immunologie - Immunopathologie - Immunothérapeutique [I3]
Titre de la revue :
Arthritis and Rheumatism
Pagination :
1306–1314
Éditeur :
Wiley
Date de publication :
2014-01-08
ISSN :
0004-3591
Mot(s)-clé(s) :
Behçet's disease
neuro-Behçet's
vasculitis
outcome
treatment
neuro-Behçet's
vasculitis
outcome
treatment
Discipline(s) HAL :
Sciences de l'ingénieur [physics]/Traitement du signal et de l'image [eess.SP]
Informatique [cs]/Traitement du signal et de l'image [eess.SP]
Informatique [cs]/Traitement du signal et de l'image [eess.SP]
Résumé en anglais : [en]
: Objective: To report the long-term outcome of neurological involvement in patients with Behçet's disease (BD). Methods: Retrospective analysis of 115 patients fulfilling the international criteria for BD [57% male with ...
Lire la suite >: Objective: To report the long-term outcome of neurological involvement in patients with Behçet's disease (BD). Methods: Retrospective analysis of 115 patients fulfilling the international criteria for BD [57% male with median [Q1-Q3] age of 37 [30-46] years] and with neuro-Behçet's disease (NBD) after exclusion of cerebral venous thrombosis. Factors associated with relapse of NBD, dependence and mortality were assessed. Results: Seventy-eight (68%) patients presented with acute NBD and 37 (32%) with a progressive course. The HLA B51 allele was carried by 49% of patients. Overall, 46/115 (40%) patients had a severe baseline disability status, represented by a Rankin score ≥ 3. The 5 and 7 years event-free survival rates were 65% and 53%, respectively. In multivariate analysis, a positive HLA-B51 status was independently associated with the risk of NBD relapse (OR=3.6 [1.5-9.1]). After a median follow-up of 73 [59-102] months, 21 (25.2%) patients became dependent or died. Factors independently associated with poor outcome were paresis at onset (OR=6.47 [1.73-24.23]) and a brainstem location of inflammatory lesions on MRI (OR=8.41 [1.03-68.43]). All 115 patients were treated with glucocorticosteroids, including 53/115 (46.1%) with cyclophosphamide and 40/115 (34.8%) with azathioprine. A trend towards longer event-free survival was observed in severe NBD patients (i.e. Rankin score ≥ 3 at onset) receiving intravenous cyclophosphamide compared with those treated with azathioprine (p =0.06). Conclusion: NBD is a severe condition in which patients with the HLA-B51 allele appear to experience a worse prognosis. © 2013 American College of Rheumatology.Lire moins >
Lire la suite >: Objective: To report the long-term outcome of neurological involvement in patients with Behçet's disease (BD). Methods: Retrospective analysis of 115 patients fulfilling the international criteria for BD [57% male with median [Q1-Q3] age of 37 [30-46] years] and with neuro-Behçet's disease (NBD) after exclusion of cerebral venous thrombosis. Factors associated with relapse of NBD, dependence and mortality were assessed. Results: Seventy-eight (68%) patients presented with acute NBD and 37 (32%) with a progressive course. The HLA B51 allele was carried by 49% of patients. Overall, 46/115 (40%) patients had a severe baseline disability status, represented by a Rankin score ≥ 3. The 5 and 7 years event-free survival rates were 65% and 53%, respectively. In multivariate analysis, a positive HLA-B51 status was independently associated with the risk of NBD relapse (OR=3.6 [1.5-9.1]). After a median follow-up of 73 [59-102] months, 21 (25.2%) patients became dependent or died. Factors independently associated with poor outcome were paresis at onset (OR=6.47 [1.73-24.23]) and a brainstem location of inflammatory lesions on MRI (OR=8.41 [1.03-68.43]). All 115 patients were treated with glucocorticosteroids, including 53/115 (46.1%) with cyclophosphamide and 40/115 (34.8%) with azathioprine. A trend towards longer event-free survival was observed in severe NBD patients (i.e. Rankin score ≥ 3 at onset) receiving intravenous cyclophosphamide compared with those treated with azathioprine (p =0.06). Conclusion: NBD is a severe condition in which patients with the HLA-B51 allele appear to experience a worse prognosis. © 2013 American College of Rheumatology.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :